Erythrocyte membrane phospholipid (None standardized; sometimes referred to generally as "RBC membrane phospholipids")

Erythrocyte membrane phospholipids make up approximately half the mass of the red blood cell membrane (the other half is protein). They are asymmetrically distributed: choline phospholipids (phosphatidylcholine, sphingomyelin) are enriched on the external leaflet, while amino phospholipids (phosphatidylserine, phosphatidylethanolamine) are concentrated on the cytoplasmic side. This asymmetry is vital for erythrocyte mechanical properties, barrier function, and processes such as blood clotting. Disruption of this composition—by genetic mutation, oxidative stress, or metabolic disease—can lead to abnormal red blood cells, premature destruction, or altered coagulation. While the membrane itself may be affected or used as a model in experimental therapeutics, there are no clinically approved drugs that target erythrocyte membrane phospholipids directly.

Other names

Red blood cell membrane phospholipidsRBC membrane phospholipids

Not applicable—no approved drugs act selectively upon erythrocyte membrane phospholipids as their primary target.